4/25/2011 8:33:12 AM
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, “Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer”. The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company’s lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy. This is the seventh patent in Pro-Pharmaceuticals growing patent portfolio that covers its core Galectin-targeting compounds and further reinforces the proprietary nature of DAVANAT®, the Company’s lead drug, in major markets around the world.
comments powered by